Geron (STU:GON) Beginning Cash Position : €106.38 Mil (As of Sep. 2024)

View and export this data going back to 1996. Start your Free Trial

What is Geron Beginning Cash Position?

Geron's Beginning Cash Position for the quarter that ended in Sep. 2024 was €106.38 Mil.

Geron's quarterly Beginning Cash Position increased from Mar. 2024 (€65.45 Mil) to Jun. 2024 (€177.33 Mil) but then declined from Jun. 2024 (€177.33 Mil) to Sep. 2024 (€106.38 Mil).

Geron's annual Beginning Cash Position increased from Dec. 2021 (€9.10 Mil) to Dec. 2022 (€33.26 Mil) and increased from Dec. 2022 (€33.26 Mil) to Dec. 2023 (€52.46 Mil).

Geron Beginning Cash Position Historical Data

The historical data trend for Geron's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Geron Beginning Cash Position Chart

Geron Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Beginning Cash Position

Get a 7-Day Free Trial

9.76

11.44

9.10

33.26

52.46

Geron Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Beginning Cash Position	Get a 7-Day Free Trial															53.82	28.65	65.45	177.33	106.38

Geron Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

Geron Beginning Cash Position Related Terms

Thank you for viewing the detailed overview of Geron's Beginning Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Geron Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Geron Corp (STU:GON) » Definitions » Beginning Cash Position

Comparable Companies

Traded in Other Exchanges

GERN:USA 0IV3:UK GON:Germany

Address

919 East Hillsdale Boulevard, Suite 250, Foster City, CA, USA, 94404

Website

https://www.geron.com

Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.

Geron Headlines

No Headlines